Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) has been given a consensus rating of “Hold” by the fourteen analysts that are presently covering the company, Marketbeat reports. Eleven research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $107.44.
Several research firms recently weighed in on LNTH. Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the company from $125.00 to $102.50 in a report on Monday, August 3rd. Mizuho lowered shares of Lantheus from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $115.00 to $109.00 in a research note on Tuesday, October 13th. CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and cut their price objective for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. Finally, B. Riley Financial downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th.
View Our Latest Stock Report on LNTH
Institutional Trading of Lantheus
Lantheus Price Performance
Lantheus stock opened at $100.10 on Monday. The company has a market cap of $6.54 billion, a price-to-earnings ratio of 24.18 and a beta of -0.06. The firm’s fifty day moving average is $100.26 and its 200 day moving average is $90.84. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. Lantheus has a 52-week low of $50.15 and a 52-week high of $111.86.
Lantheus (NASDAQ:LNTH – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. During the same quarter last year, the business earned $1.57 earnings per share. Lantheus’s quarterly revenue was up 2.7% compared to the same quarter last year. Sell-side analysts forecast that Lantheus will post 4.54 EPS for the current fiscal year.
About Lantheus
Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.
The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.
Read More
- Five stocks we like better than Lantheus
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
